Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy ...

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy ...

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

A detailed analysis reveals one of the reasons the R21/Matrix-M malaria vaccine works so well: the antibodies generated ...

Novavax ( ($NVAX) ) has risen by 24.00%. Read on to learn why. Novavax has experienced a notable 24.00% increase in its stock price over the past ...

Pulling the Pfizer EUA would remove the only COVID-19 vaccine approved for all children from the US market. The Moderna ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Novavax, with a price target of $8.00. The company’s shares closed yesterday at $7.58. Elevate ...

Under Robert F. Kennedy Jr., federal officials may withdraw an endorsement for the vaccine in younger children.

A Food and Drug Administration official who stepped down less than two weeks ago is getting his job back as the agency’s top ...